linking molecular neurobiology to therapeutic approaches for alzheimer’s disease with PET

Paul G M Luiten, Marcelo F. Masman, C. Nyakas, Ulrich Eisel, Nikoletta Dobos

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The present review is a text version of a plenary lecture given at the International Symposium on PET and SPECT in Neurology and Psychiatry on April 23, 2012, in Groningen, the Netherlands. In this communication, we will shortly review a series of experimental studies on potential mechanisms underlying the pathogenic processes of Alzheimer’s disease (AD) and how some of these mechanisms can be visualized with PET imaging. We will specifi cally focus on imaging of beta amyloid (Aâ) and how to combat Aâ aggregation. We conclude that limiting production and clearance of Aâ can be a major target for Alzheimer drug development. Furthermore, we will address the role of blood supply to the brain, the blood–brain barrier, and the fate of brain microvasculature in AD. Finally, we will argue how neuroinfl ammation in AD may lead to depression-like symptoms as a comorbidity in AD.

Original languageEnglish
Title of host publicationPet and Spect in Neurology
PublisherSpringer Berlin Heidelberg
Pages451-478
Number of pages28
ISBN (Print)9783642543074, 9783642543067
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Neurobiology
Alzheimer Disease
Brain
Therapeutics
Neurology
Microvessels
Single-Photon Emission-Computed Tomography
Amyloid
Netherlands
Psychiatry
Comorbidity
Depression
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Luiten, P. G. M., Masman, M. F., Nyakas, C., Eisel, U., & Dobos, N. (2014). linking molecular neurobiology to therapeutic approaches for alzheimer’s disease with PET. In Pet and Spect in Neurology (pp. 451-478). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-54307-4_20

linking molecular neurobiology to therapeutic approaches for alzheimer’s disease with PET. / Luiten, Paul G M; Masman, Marcelo F.; Nyakas, C.; Eisel, Ulrich; Dobos, Nikoletta.

Pet and Spect in Neurology. Springer Berlin Heidelberg, 2014. p. 451-478.

Research output: Chapter in Book/Report/Conference proceedingChapter

Luiten, PGM, Masman, MF, Nyakas, C, Eisel, U & Dobos, N 2014, linking molecular neurobiology to therapeutic approaches for alzheimer’s disease with PET. in Pet and Spect in Neurology. Springer Berlin Heidelberg, pp. 451-478. https://doi.org/10.1007/978-3-642-54307-4_20
Luiten PGM, Masman MF, Nyakas C, Eisel U, Dobos N. linking molecular neurobiology to therapeutic approaches for alzheimer’s disease with PET. In Pet and Spect in Neurology. Springer Berlin Heidelberg. 2014. p. 451-478 https://doi.org/10.1007/978-3-642-54307-4_20
Luiten, Paul G M ; Masman, Marcelo F. ; Nyakas, C. ; Eisel, Ulrich ; Dobos, Nikoletta. / linking molecular neurobiology to therapeutic approaches for alzheimer’s disease with PET. Pet and Spect in Neurology. Springer Berlin Heidelberg, 2014. pp. 451-478
@inbook{eb95c663b2f74e68b733726de3550799,
title = "linking molecular neurobiology to therapeutic approaches for alzheimer’s disease with PET",
abstract = "The present review is a text version of a plenary lecture given at the International Symposium on PET and SPECT in Neurology and Psychiatry on April 23, 2012, in Groningen, the Netherlands. In this communication, we will shortly review a series of experimental studies on potential mechanisms underlying the pathogenic processes of Alzheimer’s disease (AD) and how some of these mechanisms can be visualized with PET imaging. We will specifi cally focus on imaging of beta amyloid (A{\^a}) and how to combat A{\^a} aggregation. We conclude that limiting production and clearance of A{\^a} can be a major target for Alzheimer drug development. Furthermore, we will address the role of blood supply to the brain, the blood–brain barrier, and the fate of brain microvasculature in AD. Finally, we will argue how neuroinfl ammation in AD may lead to depression-like symptoms as a comorbidity in AD.",
author = "Luiten, {Paul G M} and Masman, {Marcelo F.} and C. Nyakas and Ulrich Eisel and Nikoletta Dobos",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-3-642-54307-4_20",
language = "English",
isbn = "9783642543074",
pages = "451--478",
booktitle = "Pet and Spect in Neurology",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - linking molecular neurobiology to therapeutic approaches for alzheimer’s disease with PET

AU - Luiten, Paul G M

AU - Masman, Marcelo F.

AU - Nyakas, C.

AU - Eisel, Ulrich

AU - Dobos, Nikoletta

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The present review is a text version of a plenary lecture given at the International Symposium on PET and SPECT in Neurology and Psychiatry on April 23, 2012, in Groningen, the Netherlands. In this communication, we will shortly review a series of experimental studies on potential mechanisms underlying the pathogenic processes of Alzheimer’s disease (AD) and how some of these mechanisms can be visualized with PET imaging. We will specifi cally focus on imaging of beta amyloid (Aâ) and how to combat Aâ aggregation. We conclude that limiting production and clearance of Aâ can be a major target for Alzheimer drug development. Furthermore, we will address the role of blood supply to the brain, the blood–brain barrier, and the fate of brain microvasculature in AD. Finally, we will argue how neuroinfl ammation in AD may lead to depression-like symptoms as a comorbidity in AD.

AB - The present review is a text version of a plenary lecture given at the International Symposium on PET and SPECT in Neurology and Psychiatry on April 23, 2012, in Groningen, the Netherlands. In this communication, we will shortly review a series of experimental studies on potential mechanisms underlying the pathogenic processes of Alzheimer’s disease (AD) and how some of these mechanisms can be visualized with PET imaging. We will specifi cally focus on imaging of beta amyloid (Aâ) and how to combat Aâ aggregation. We conclude that limiting production and clearance of Aâ can be a major target for Alzheimer drug development. Furthermore, we will address the role of blood supply to the brain, the blood–brain barrier, and the fate of brain microvasculature in AD. Finally, we will argue how neuroinfl ammation in AD may lead to depression-like symptoms as a comorbidity in AD.

UR - http://www.scopus.com/inward/record.url?scp=84956800853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956800853&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-54307-4_20

DO - 10.1007/978-3-642-54307-4_20

M3 - Chapter

SN - 9783642543074

SN - 9783642543067

SP - 451

EP - 478

BT - Pet and Spect in Neurology

PB - Springer Berlin Heidelberg

ER -